<DOC>
	<DOCNO>NCT02261727</DOCNO>
	<brief_summary>The aim multi-centre , double blind , randomise , control trial ( DBRCT ) assess effect low dose theophylline , singly combination low dose oral prednisone , COPD ( Chronic Obstructive Pulmonary Disease ) exacerbation , quality life secondary clinical outcome compare usual therapy placebo 48 week treatment . Approximately 2400 symptomatic patient COPD recruit China comparison low dose theophylline versus placebo low dose theophylline + low dose prednisone The primary end-point study difference three treatment group - COPD exacerbation rate - Time first severe exacerbation require hospitalisation death</brief_summary>
	<brief_title>Theophylline Steroids Chronic Obstructive Pulmonary Disease ( COPD ) Study</brief_title>
	<detailed_description>The investigator hypothesise patient COPD beneficial response low dose theophylline prednisone , superior placebo low dose theophylline alone , reflect range clinical outcome . The study aim demonstrate treatment low dose oral prednisone low dose , slow release theophylline compare low dose , slow release theophylline placebo reduce COPD exacerbation improve range secondary outcome include quality life , CAT score , hospital admission lung function . Eligible participant randomise one three treatment arm DBRCT receive placebo OR low-dose theophylline ( 100 mg twice day ) OR low-dose theophylline 100 mg twice day ( BD ) plus low-dose prednisone ( 5 mg day ) Patients eligible inclusion follow criterion meet : - Current former smoker ( &gt; 10 pack year ) biomass exposure - 40 - 80 year age - Clinical diagnosis COPD - Post-bronchodilator forced expiratory volume one second ( FEV1 ) &lt; 70 % predict - Post bronchodilator FEV1/forced vital capacity ( FVC ) ratio &lt; 0.7</detailed_description>
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases , Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Theophylline</mesh_term>
	<criteria>Current former smoker ( &gt; 10 pack year ) biomass exposure 40 80 year age Clinical diagnosis COPD Postbronchodilator FEV1 &lt; 70 % predict Post bronchodilator FEV1/FVC ratio &lt; 0.7 Life expectancy le 12 month Exacerbation respiratory infection within 4 week prior randomisation Patient take require maintenance oral corticosteroid Patient domiciliary oxygen There previous pulmonary resection Previous sensitivity , intolerance theophylline Coexistent illness preclude participation study ( epilepsy , chronic liver disease , unstable cardiovascular disease , diabetes , active malignancy ) Inability complete quality life questionnaire Concomitant major illness would interfere visit , assessment followup Have evidence chronic liver disease , transaminase gammaglutamyltransferase ( GGT ) elevation &gt; 1.5 x upper limit normal ( ULN ) Random blood glucose level &gt; 8mmol/L High chance view treat physician patient adhere study treatment follow</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>COPD</keyword>
	<keyword>Theophylline</keyword>
	<keyword>Oral corticosteroid</keyword>
	<keyword>COPD exacerbation</keyword>
</DOC>